Insights into the Binding Modes of Human Β3-Adrenergic Receptor Agonists with Ligand-Based and Receptor-Based Methods

Fangfang Jin,Chunhua Lu,Xianqiang Sun,Weihua Li,Guixia Liu,Yun Tang

DOI: https://doi.org/10.1007/s11030-011-9311-8

2011-01-01

Molecular Diversity

Abstract:Agonists of β3-adrenergic receptor (AR) have been thought as potential drugs for the treatment of obesity, type II diabetes, and overactive bladder. In order to clarify the essential structure–activity relationship and the detailed binding modes of β3-AR agonists as well as to identify new lead compounds activating β3-AR, ligand-based and receptor-based methods were applied. The pharmacophore models were developed based on 144 β3-AR agonists. Meanwhile, the homology model of the β3-AR was built based on the crystal structure of β2-AR. The pharmacophore model and the homology model mapped with each other very well, and some important information was obtained from the docking result. For example, agonists formed similar hydrogen-bonding interactions with residues Asp117, Arg315, and Asn332, π–π stacking interaction with residues Phe308, and hydrophobic interactions with residues Val118, Val121, Ala197, Phe198, Ala199, Phe309, and Phe328 of β3-AR. And the major difference about binding mode from the crystal structures of β1- and β2-ARs is the hydrogen-bonding interaction with the residue Arg315, which corresponds to the residue Asn313 of β1-AR and the residue His296 of β2-AR, respectively. Our findings may be crucial for the design and development of novel selective and potent β3-AR agonists.